New hope for tough childhood cancer: early drug trial opens
NCT ID NCT07297979
Summary
This early-stage study is testing a new drug called xaluritamig in children, teens, and adults with Ewing sarcoma that has returned or hasn't responded to standard chemotherapy. The main goals are to find a safe dose and understand how the body processes the drug. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90995-1752, United States
Conditions
Explore the condition pages connected to this study.